Dramatic Improvement of Subcutaneous Insulin Resistance with Nafamostat Ointment Treatment
- Satoshi Kawashima, MD,
- Hideaki Kaneto, MD, PHD,
- Ken'ya Sakamoto, MD, PHD,
- Ikuko Honsho, MD,
- Tetsuyuki Yasuda, MD, PHD,
- Akio Kuroda, MD, PHD,
- Toshihiko Shiraiwa, MD, PHD,
- Ryuichi Kasami, MD,
- Taka-aki Matsuoka, MD, PHD,
- Yoshimitsu Yamasaki, MD, PHD and
- Munehide Matsuhisa, MD, PHD
- From Osaka University, Osaka, Japan
- Address correspondence to Hideaki Kaneto, MD, PhD, Internal Medicine and Therapeutics (A8), Osaka University, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail: kaneto{at}medone.med.osaka-u.ac.jp
Subcutaneous insulin resistance is characterized by a lack of biological efficacy of subcutaneously injected insulin, with retained sensitivity to intravenously injected insulin. The existence of increased insulin-degrading activity has been suggested as a possible underlying mechanism (1). It has been reported that protease inhibitors exert beneficial effects on the absorption of subcutaneously injected insulin (1). Although the effect of an ointment containing a protease inhibitor has been shown in normal volunteers (2), there has been no report on the ointment's effect in patients with subcutaneous insulin resistance. This is …
